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doi:10.1016/j.jtcvs.2006.05.015ackground: The role of neoadjuvant chemotherapy and radiation therapy before
esection in esophageal cancer remains controversial. Operative risks may be
ncreased, but this has not been systematically addressed in published trials or
eports.
ethods: This was a prospective, nonrandomized, restricted cohort design of
atients (n  200) from 1997 to 2003 with resectable cancer of the esophagus or
sophagogastric junction. A total of 102 patients underwent multimodal therapy
ith 5-fluorouracil, cisplatin, and radiation therapy before surgery, and 98 patients
pted for surgery alone. In-hospital mortality and morbidity were the primary end
oints, and cancer survival was a secondary end point.
esults: In patient cohorts matched for operative risk factors, the odds ratio for
ostoperative sepsis (P .007), respiratory failure (P .009), and acute respiratory
istress syndrome (P  .02) was increased in the multimodal group. There was no
ignificant difference between groups comparing median and 1-, 2-, and 3-year
urvivals.
onclusions: Multimodal therapy was associated with increased respiratory and
eptic complications compared with a surgery-only cohort undergoing the equiva-
ent surgery. Respiratory failure was in most cases idiopathic. The data suggest that
fforts should be made to limit radiation lung exposure in multimodal regimens, and
o understand and modulate the local and systemic effects of preoperative chemo-
adiation.
arcinoma of the esophagus and gastroesophageal junction represents aggres-
sive disease with a poor prognosis even in patients undergoing curative
resection.1,2 Where squamous cell histology once predominated, the inci-
ence of esophageal adenocarcinoma in the Western world has increased dramati-
ally over the past 3 decades.3,4 Surgical resection remains the standard of care for
ost esophageal surgeons, but even with en bloc resections and radical 2- or 3-field
ymphadenectomy, 3-year survival rarely exceeds 40%.5-7
The disappointing outcomes from surgery alone have resulted in considerable
nterest in multimodal approaches, either neoadjuvant chemotherapy alone or com-
ined with radiation therapy.1 However, the interpretation of randomized clinical
rials to date is controversial. For chemotherapy alone, an appropriately powered
andomized study (Intergroup Trial) of 440 North American patients showed no
enefit from a preoperative and postoperative combination of 5-fluorouracil and
isplatin, with a 2-year survival of 35% in the combination group compared with
7% in the group treated with surgery alone.8 In contrast, a similar study from the
nited Kingdom of 802 patients reported an improved survival at 2 years (43% vs
4%) in the combined modality group.9 Analysis of trials of combination chemo-
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TSherapy and radiation therapy before surgery,10-16 and meta-
nalysis,17,18 is also difficult for several reasons: Only 2 of
 studies,13,15 both negative, appear adequately powered
ith more than 200 patients; there is a mix of pathologic
ypes, adenocarcinoma and squamous cell cancer, in all but
 study;12 the total dose of radiation therapy administered
and treatment fractions) is different across trials; and the
nterpretation of the 1 trial showing a benefit for multimodal
herapy12 (undertaken in patients with adenocarcinoma at
his center between 1990 and 1995) is complicated by
elatively small numbers, limited cross-sectional imaging in
reoperative staging, and an outcome in the surgery alone
rm below standard benchmarks. The most recent trial, an
dequately powered Australasian study of 256 patients,
1% of whom had adenocarcinoma, failed to show a sur-
ival benefit from neoadjuvant chemoradiotherapy.16
Notwithstanding the controversy whether oncologic ben-
fit accrues from multimodal regimens, informed decision-
aking requires better information on other end points,
ncluding quality of life outcomes, toxicity of neoadjuvant
egimens, and operative complications. Intuitively, the ad-
inistration of chemotherapy and radiation therapy before
ajor surgery presents an added challenge, both through
reatment-related immunosuppression and direct tissue tox-
city from radiation. One large randomized trial13 was stopped
ecause of increased postoperative mortality and morbidity
n the multimodal group, and in other trials operative out-
omes have not been rigorously reported. In this report,
ostoperative complications are reported in detail from a
rospective cohort of patients undergoing multimodal ther-
py. A contemporaneous cohort undergoing surgery alone,
ut equivalent in clinical stage, risk factors, performance
tatus, and magnitude of surgery, served as a comparison
roup. This article highlights the apparent added risks of
ultimodal therapy, in particular that of idiopathic respira-
ory failure.
atients and Methods
ligibility Criteria
he inclusion criteria for multimodal therapy of esophageal ade-
ocarcinoma or squamous cell cancer approved by the institutional
eview board at this center is as follows:12 age less than 77 years;
atisfactory performance status and medical fitness for surgery,
ncluding subjective evaluation by the surgeon, American Society
f Anesthesiologists score (1 or 2), Karnofsky index (90%), and
espiratory physiology (forced expiratory volume in 1 second at
Abbreviations and Acronyms
ARDS acute respiratory distress syndrome
CT  computed tomography
POD  postoperative dayinimum of 1.5 L); leukocyte count greater than 3500/mm3, s
50 The Journal of Thoracic and Cardiovascular Surgery ● Septelatelet count greater than 100,000/mm3, serum creatinine less
han 124 mol/L; and no previous chemotherapy or radiation
herapy. Patients receiving this treatment regimen were compared
ith patients treated with surgery alone who also fulfilled these
ame criteria. Patients with any one of the following were excluded
rom this analysis: age more than 77 years; high-grade dysplasia or
arcinoma in situ; emergency esophagectomy after esophageal
upture; surgery determined preoperatively to be palliative based
n tumor extent or patient performance; evidence of bronchial
nvasion based on computed tomography (CT) imaging and bron-
hoscopy; tumor classified as T4, Nany by the multidisciplinary
sophageal panel; and resections not involving a thoracotomy,
ncluding transhiatal resections and total gastrectomy.
All patients underwent clinical examination, esophagoscopy,
nd computerized tomography of the neck, thorax, and abdomen.
ndoscopic ultrasound was not routinely used because its access is
imited at this center. 18F-deoxyglucose positron emission tomog-
aphy scans are now routine, but became available only in mid-
003. With CT criteria, the mediastinal and left gastric nodes were
lassified as N1 (invaded) if the maximal transverse diameter of
hese nodes was larger than 1 cm. Resectable disease was defined
s T1-3, N0-1. All tumors at the esophagogastric junction were
ssigned as Type I, II, or III, per Siewert and Stein:17 Type I is
denocarcinoma of the distal esophagus, usually arising in special-
zed intestinal metaplasia; Type II is a true adenocarcinoma of the
ardia arising immediately at the esophagogastric junction; and
ype III is a subcardial gastric carcinoma infiltrating the esopha-
ogastric junction and distal esophagus from below. Patients with
ype II and III junctional tumors underwent a staging laparoscopy
s part of their workup.
All patients since 1997 with localized disease (T2-3, N0-1; pre-
icted R0 resection) of the esophagus or junction (Type I and II)
ere offered the option of either surgery alone or the multimodal
egimen; patients with Type III esophagogastric junction tumors
ad surgery alone. Patients if medically fit with locally advanced
nresectable disease were treated with radical radiation therapy
nd chemotherapy and no consideration of surgery.
eoadjuvant Therapy
he majority of patients (n 49) in the neoadjuvant treatment arm
ere given a standard protocol of chemoradiotherapy consisting of
0 Gy/15 fractions on days 1 to 5, 8 to 12, and 15 to 19, and
oncurrent chemotherapy of 5-fluorouracil (15 mg/kg) on days 1 to
 and cisplatin (75 mg/m2) on day 7.12 Chemotherapy was re-
eated on week 6. Since 2002 an increasing number of patients
n  41) have been given 44 Gy in 22 fractions. Three patients in
his analysis were referred from another institution where they
ad received 50 Gy in 25 fractions. In the remaining patients, 8
eceived 40 Gy in 20 fractions, and 1 received 45 Gy in 25
ractions. Patients were restaged by CT and esophagoscopy at
eek 8 and scheduled for surgery at week 9. Surgery took place if
he neutrophil count was greater than 2  106/mL-1, the perfor-
ance status had not significantly deteriorated, and there was no
vidence of local or systemic progression of disease on imaging.
urgical Procedure
ll patients underwent a thoracotomy as a component of theirurgical management, either combined with an abdominal and
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G
TSeck exploration (3-stage) for mid and upper-esophageal cancers,
r cancer arising in long-segment Barrett’s esophagus, or with an
bdominal exploration (2-stage) for most lower third and junc-
ional tumors, or combined with a total gastrectomy for junctional
umors with significant gastric extension (Type III). A 2-field
ymphadenectomy (abdominal and thoracic) was performed in all
ases. All patients were extubated immediately after surgery and
anaged in a high-dependency unit. All patients with a gastric
emnant underwent a pyloroplasty, and patients were fed enterally
rom 12 hours postoperatively through a needle catheter jejunos-
omy. A Gastrografin contrast study was routinely performed on
ostoperative day (POD) 7 or 8 before initiating oral fluids.
ostoperative Complications
ll complications from surgery to discharge from hospital were
rospectively documented. Respiratory failure was defined as the
equirement for mechanical ventilation beyond 24 hours after
urgery. Acute respiratory distress syndrome (ARDS) and multiple
rgan failure were defined as per Bone and colleagues,18 sepsis
equired evidence of systemic inflammatory response syndrome
ith microbiologic evidence of infection, and the diagnosis of
neumonia required positive sputum cultures or clear clinical and
adiographic evidence of consolidation.
tatistical Analysis
tatistical analysis was performed using STATA statistical pack-
ge, version 8.2 for Windows (StataCorp, College Station, Tex).
uantitative data are expressed as median and 95% confidence
ntervals. Qualitative data are described as percentages. Postoper-
tive complications were compared using the Mann Whitney
test. Univariate and multivariate logistic regression models were
sed to identify the odds ratio of postoperative morbidity and
ortality. Operative mortality was defined as any death within the
ospital after surgery. Actuarial survival was calculated from the
ate of first treatment by the Kaplan-Meier method, and compar-
sons between the groups were made by the log-rank test.
esults
atient Demographics
n this period, resection with curative intent (anticipated R0)
as undertaken in 200 patients. The patients in each group
re shown in Table 1, with 102 in the multimodal group and
8 in the surgery only group. The median age at diagnosis
as 59 years in the multimodal group and 63 years in the
urgery only group (P  .08). The multimodal group had
ignificantly (P  .05) better forced expiratory volume in 1
econd, but there was no difference between groups in
erformance status, American Society of Anesthesiologists
rades, nutritional status, or comorbid disease. Adenocarci-
oma was the predominant pathology, 75% in the multimo-
al group and 59% in the surgery group (P  .03).
linical and Pathologic Staging
here was no significant difference in clinical staging be-
ween the surgery-only and multimodal groups (Table 1),
ith 31% and 33%, respectively, staged as clinical Stage 3 o
The Journal of ThoracicP  not significant). Fourteen patients (14%) in the mul-
imodal group did not progress to surgery, because of wors-
ning performance status in 5 cases and evidence of disease
rogression to locally unresectable or metastatic disease in
cases.
Surgery was undertaken in 98 patients in the surgery
ABLE 1. Clinical, operative, and pathologic details
emographic details
Surgery only
(n  98)
Multimodal
(n  102)
ex: male/female 69/29 82/20
ge (y): median (range) 63 (29-76) 59 (32-74)
ody mass index (%)
25 39 (40) 38 (37)
25-30 35 (36) 43 (42)
30 10 (10) 18 (18)
Unknown 14 (15) 3 (3)
moking status (%)
Never smoked 32 (33) 27 (27)
Ex-smoker (1 year) 34 (34) 41 (40)
Current smoker 32 (33) 34 (33)
omorbid disease and performance
status (%)
No comorbid disease 23 (24) 30 (29)
Karnofsky  90% 94 (96) 102 (100)
ASA Grade I or 2 94 (96) 99 (98)
Median FEV1 (L) 2.6 2.9*
umor site (%)
Upper esophagus 4 (2) 1 (1)
Middle esophagus 22 (23) 16 (16)
Lower esophagus 32 (34) 51 (50)
Junctional (Types 2 and 3) 40 (41) 34 (31)
istology (%)
Adenocarcinoma/squamous 58/40 77/25*
linical stage (%)
Stage 1 9 (7) 2 (2)
Stage 2 59 (62) 66 (65)
Stage 3 30 (31) 34 (33)
ompleted treatment (%) 98 (100) 88 (86)
athologic stage (%)
Stage 0 — 16 (18)*
Stage 1 15 (16) 15 (17)
Stage 2 38 (38) 35 (40)
Stage 3 45 (46) 22 (25)
peration details (%)
3-stage esophagectomy 31 (32) 19 (22)
2-stage esophagectomy 51 (52) 68 (77)
Total gastrectomy and distal
esophagectomy
16 (16) 1 (1)
esidual tumor status (patients
who underwent resection)
R0 resection 81 (83) 76 (86)
R1 resection 17 (17) 12 (14)
SA, American Society of Anesthesiologists; FEV1, forced expiratory vol-
me in 1 second. *P  .05 surgery vs multimodal.nly group and in 88 patients in the multimodal group.
and Cardiovascular Surgery ● Volume 132, Number 3 551
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G
TSixteen patients (18%) achieved a complete pathologic re-
ponse to neoadjuvant therapy, and 25% of patients in the
ultimodal group had Stage 3 disease compared with 46%
n the surgery only group (P  .01 pathologic staging com-
aring multimodal and surgery only group).
n-Hospital Complications
n-hospital morbidity and mortality are shown in Table 2.
ix patients died (7%) in the multimodal group, compared
ith 4 patients (4%) in the surgery only group (P  .3).
here was a significant increase in sepsis (P  .007),
espiratory failure (P  .03), and ARDS (P  .008) in the
ultimodal group. The odds ratio (95% confidence interval;
value) was 7.02 (1.7-29; P .007) for sepsis, 6.9 (1.6-19;
 .009) for respiratory failure, and 13.3 (1.4-122; P 
ABLE 2. In-hospital postoperative morbidity and mortality
Multimodal
(n  88)
Surgery
(n  98) P value
epsis 13 (15%) 3 (3%) .007
espiratory failure 12 (14%) 4 (4%) .03
RDS 9 (10%) 1 (1%) .008
ortality 6 (7%) 4 (4%) .5
eart failure 2 (2%) 0 .22
rrhythmia 6 (7%) 4 (4%) .52
nastomotic leak 5 (6%) 2 (2%) .26
enal dysfunction 5 (6%) 3 (3%) .48
neumonia 9 (10%) 8 (8%) .67
leural effusion 26 (30%) 21 (22%) .3
ulmonary embolus 1 (1%) 2 (2%) .86
epression 2 (2%) 4 (4%) .68
hylothorax 4 (5%) 3 (3%) .71
erebrovascular accident 0 1 (1%) .9
RDS, acute respiratory distress syndrome.
ABLE 3. Major thoracic morbidity and mortality in multim
Age (y)/Sex Complications Path
1. 63/M ARDS, MOF
2. 61/M RF
3. 63/M ARDS, RF
4. 74/M RF, ARDS
5. 32/F ARDS, RF
6. 62/F ARDS, RF
7. 49/M RF
8. 49/M RF
9. 65/M RF
10. 49/M RF, ARDS
11. 59/F RF/ARDS/sepsis
12. 66/M RF
13. 70/M RF
14. 74/M ARDS
RDS, acute respiratory distress syndrome; RF, respiratory failure; M
Postoperative day of death.
52 The Journal of Thoracic and Cardiovascular Surgery ● Septe.02) for ARDS in the multimodal group compared with
urgery alone. There was no difference in other complica-
ions, in particular pneumonia, arrhythmia, pulmonary em-
olus, and anastomotic leak. Comparing the multimodal
ith surgery only groups, there was no significant differ-
nce in the median estimated blood loss (400 vs 550 mL,
espectively), median blood transfusions (0 vs 0, respec-
ively), median days ventilated (0 vs 0, respectively), and
ength of stay in the high-dependency unit or intensive care
nit (3 vs 3, respectively).
The cause of the 4 in-hospital deaths, all in male patients
n their sixth decades, and the POD of death in the surgery
nly group were as follows: mesenteric infarction (POD 8),
ulmonary embolus (POD 1), respiratory failure (POD 12),
nd sepsis and fulminant multiple organ failure (POD 5)
rom a microscopic anastomotic leak identified at postmor-
em. In the multimodal group, all deaths were related to
espiratory complications. The details of these patients and
ther major respiratory complications in this cohort are
hown in Table 3. Of note, 3 of 6 patients who died had a
omplete pathologic response to neoadjuvant therapy, and
n all 3 patients, 2 of who had autopsies, no evidence of
nfection/sepsis/leak was uncovered. Two patients died who
ad chemoradiation therapy delivered by another group; 1
atient had received 50 Gy, and both were debilitated from
heir neoadjuvant treatment but fulfilled the standard criteria
or surgery.
urvival
fter a median follow-up of 26 months, based on intention-
o-treat analysis, the median survival in the multimodal
roup was 26 months compared with 29 months in the
urgery alone group. The 1-, 2-, and 3-year survivals in the
ultimodal group were 68%, 53%, and 33%, respectively,
l group
c stage Radiation therapy* Died†
0 40/2.6 29
0 40/2.6 69
0 50/2 28
1 40/2.6 11
0 44/2 42
1 44/2 98
1 40/2.6
1 44/2
0 44/2
1 40/2.6
0 44/2
0 40/2.6
0 40/2.6
0 40/2.6
ultiple organ failure. *Total dose of radiation and radiation fraction.oda
ologi
T0N
T3N
T0N
T3N
T0N
T2N
T3N
T3N
T0N
T3N
T3N
T2N
T3N
T0N
OF, mmber 2006
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G
TSompared with 75%, 57%, and 45%, respectively, in the
urgery alone group (P  .3).
For adenocarcinoma alone, the median survival was 27
onths in both groups (Figure 1). The 1, 2, and 3-year
urvivals in the multimodal group were 74%, 57%, and
4%, respectively, compared with 74%, 55%, and 43%,
espectively, in the surgery alone group. For R0 resections
lone, the 1, 2, and 3-year survivals in the multimodal group
ere 80%, 63%, and 42%, respectively, compared with
3%, 61%, and 42%, respectively, in the surgery only group
P  .5).
iscussion
sophagectomy carries a significant risk of postoperative
orbidity and mortality. Earlam and Cunha-Melo19 re-
orted an overall mortality rate of 29% from articles pub-
ished between 1960 and 1979, and Muller and colleagues20
eported a postoperative mortality rate of 13% from articles
ublished between 1980 and 1988. In a review by Jamieson
nd colleagues21 of 70,756 patients, the reported mortality w
The Journal of Thoracicate was 6.7% between 1990 and 2000. Bailey and col-
eagues22 reviewed 1777 patients with esophageal cancer
ho underwent resection at 109 Veterans Affairs hospitals
etween 1991 and 2000, and reported an approximate 50%
ajor morbidity rate and 10% mortality rate. In the United
ingdom, McCulloch and colleagues23 reported a 14% in-
ospital mortality rate from a multicenter review of 365
atients. The compelling recent literature linking better out-
omes with surgeon and hospital volume has highlighted the
nassailable fact that there is no common elective surgical
rocedure that carries the same operative risks.24,25 It seems
ntuitive that factors that impact on immune well-being and
rgan function, in particular respiratory function, may have
reat relevance to operative outcome after thoracic surgery,
nd in this regard rigorous assessment of the impact of neo-
djuvant chemotherapy and radiation therapy is imperative.
This report represents the experience of a unit with a
igh-volume surgeon and support team, with approximately
0 esophageal resections per year, in a tertiary cancer center
Figure 1. Survival estimates: adenocarcinoma
only.ith a long tradition of managing patients with esophageal
and Cardiovascular Surgery ● Volume 132, Number 3 553
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G
TSnd thoracic malignancy. The groups compared are not
andomized but are contemporaneous and equal in fulfilling
trict criteria for surgery, including absence of T4 or M1
isease on CT imaging, and adequate performance status.
he type and magnitude of surgery, with a thoracotomy in
ll patients, are similar in both groups, as was the metabolic
nd immuno-inflammatory response reflected by albumin,
lucose, and C-reactive levels in the postoperative period
data not shown). The in-hospital mortality rate was 7% in
he multimodal group compared with 4% in patients treated
ith surgery alone. Although this increase in mortality was
ot significant, a highly significant increase in ARDS, re-
piratory failure, and sepsis was observed, and the respi-
atory complications were directly related to death in all
atients in the multimodal group. Inexplicably, no precipi-
ating factor was identified in 4 cases; in particular, there
as no evidence of pneumonia, anastomotic leak, or gastric
schemia. Moreover, 3 of 16 patients (19%) who had a
omplete pathologic response to preoperative therapy died
f respiratory failure; this response was idiopathic in 2
ases and related to mediastinal sepsis in 1 case, perhaps
uggesting a link between the tumor response and an exag-
erated normal tissue response.
This added operative risk of multimodal therapy has
eceived little direct attention in the literature. In the Vet-
rans Affairs study, Bailey and colleagues22 reported that
eoadjuvant therapy was independently associated with peri-
perative mortality. In a recent meta-analysis of randomized
ontrolled trials, Fiorica and colleagues26 reported increased
ostoperative mortality, from 22 of 355 patients (6%) treated
ith surgery alone to 39 of 328 patients (12%) treated with
ultimodal therapy (odds ratio 2.1, confidence interval 1.18-
.7, P  .001). In a study of patients with only adenocar-
inoma, Walsh and associates12 found an increase in peri-
perative mortality (10.7% vs 3.7%) in the multimodal
roup, and Nygard and colleagues10 observed a 1.8-fold
24% vs 13%) increase in the multimodal group. The short-
erm postoperative risk of multimodal therapy was high-
ighted in the multicenter, randomized, controlled trial
erformed by Bosset and coworkers13 in France. In an
dequately powered study of 297 patients with esophageal
quamous cell cancer, this group reported that 17 of 138
atients with multimodal therapy died after surgery, com-
ared with 5 of 137 patients in the surgery only group, and
his difference was the result of respiratory failure and
ediastinal infection. This study was criticized for larger
ractions of radiation, with a fractional dose of 3.7 Gy
ompared with 1.8 to 2.67 Gy per fraction in other trials.
The best surgical outcomes in multimodal regimens was
chieved in a small randomized trial performed by Urba and
olleagues,14 who used a hyperfractionated regimen, with
.67 Gy per fraction; only 1 of 47 patients died after
ranshiatal esophagectomy. In this study, the fractional dose m
54 The Journal of Thoracic and Cardiovascular Surgery ● Septedministered was 2 to 2.67 Gy, and no significant pattern of
ifference was evident between these 2 regimens. Normal
issue radiation response is a dynamic process involving
nflammatory responses, tissue repair processes, altered
ell–cell communication, changes in cytokines, and radia-
ion fibrosis.27 The genetic characteristics of the host, more-
ver, can impact on the radiation response. It is impossible
o spare the lung from preoperative treatment planning, but
hether idiopathic ARDS or respiratory failure relates to
riming or sensitizing of immunoinflammatory cells in the
ung to the further effect of 1-lung anesthesia and the trauma
f surgery, or acts through alternate mechanisms, requires
urther study. The role of the immunosuppressive effect of
hemotherapy is unclear. Heidecke and colleagues28 re-
orted a defective proliferation of T cells in patients after
hemoradiotherapy, when compared with patients undergo-
ng esophagectomy alone. The standard requirement before
urgery is for adequate neutrophil count recovery, but
hether neutrophils, lymphocytes, and other cells actually
unction normally in the blood, lungs, and other tissues is
nknown, and this is the subject of our current laboratory
esearch.
This study was not randomized, and potential biases may
xist. Nonetheless, this should not apply to the primary end
oint, that is, postoperative complications. The operative
nsult was similar in both groups, and all patients underwent
thoracotomy and 1-lung anesthesia as components of their
urgery. The patients in the multimodal group were younger,
ad significantly superior preoperative pulmonary function
est results, and had a lower pathologic stage compared with
he surgery only group, suggesting strongly that the nega-
ive impact of the only variable, chemoradiation, is a true
ffect.
The study was an observational study with a restricted
ohort design, and this adapts principles of the randomized,
ontrolled trial design as follows:29 The baseline criteria
ere identified for patient eligibility; inclusion and exclu-
ion criteria were the same as in randomized trials; and
tatistical methods, including intention-to-treat analysis,
ere similar to that of randomized trials. The authors rec-
gnize that cancer outcomes in a nonrandomized compari-
on should be extrapolated with caution; nevertheless, in
ohorts with an identical preoperative clinical stage no
ifference in overall outcomes was observed, or any differ-
nce where outcomes for adenocarcinoma alone were ana-
yzed. At a minimum, these cancer outcome data support the
onclusion of a recent trial16 that a randomized trial would
equire the enrollment of many hundreds of patients to be
dequately powered.
onclusions
n patients matched for performance status, tumor stage, and
agnitude of operative insult, this study highlights postop-
mber 2006
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G
TSrative respiratory complications associated with neoadju-
ant chemoradiation, as well as an increased incidence of
epsis. Patients attending this unit are informed of this risk,
nd we continue to offer the multimodal regimen to patients
ith good respiratory reserve. Efforts should be made to
oth minimize lung exposure to radiation and understand
he immunologic consequences of chemoradiation both at
he systemic level and the tissue level. Large randomized
rials are required to establish Grade A evidence for multi-
odal approaches, and we urge rigorous prospective anal-
sis and reporting of operative complications in trials that
ncompass a multimodal arm. Perhaps studies of inflamma-
ion biology modulators, including free-radical scavengers,
entoxifylline, and angiotensin-converting enzyme inhibi-
ors, may have rationale in the design of future clinical trials
hat encompass mediastinal irradiation.30
eferences
1. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med. 2003;349:
2241-52.
2. Daly JM. Esophageal cancer: results of an American College of
Surgeons Patient Care Evaluation Study. J Am Coll Surg. 2000;190:
562-72.
3. Blot WJ, De Vesa SS, Kneller RW, Fraumeni JF Jr. Rising incidence
of adenocarcinoma of the oesophagus and gastric cardia. JAMA. 1991;
265:1287-9.
4. Pera M, Cameron A, Trastek V, Carpenter H, Zermeister A. Increasing
incidence of adenocarcinoma of the esophagus and esophagogastric
junction. Gastroenterology. 1993;104:510-13.
5. Altorki N, Kent M, Ferrara RN, Port J. Three-field lymph node
dissection for squamous cell and adenocarcinoma of the esophagus.
Ann Surg. 2002;236:177-83.
6. Lerut T, Coosemans W, De Leyn P, et al. Reflections on 3-field
lymphadenectomy in carcinoma of the esophagus and gastroesopha-
geal junction. HepatoGastroenterology. 1999;46:717-25.
7. Siewert JR, Stein HJ, Feith M, et al. Histologic tumor type is an
independent prognostic parameter in esophageal cancer: lessons from
more than 1000 consecutive resections at a single centre in the western
world. Ann Surg. 2001;232:94-103.
8. Kelsen DP, Ginsberg R, Pajak TF, et al. Chemotherapy followed by
surgery compared with surgery alone for localized esophageal cancer.
N Engl J Med. 1998;339:1974-84.
9. Medical Research Council Oesophageal Cancer Working Group. Sur-
gical resection with or without preoperative chemotherapy in oesoph-
ageal cancer: a randomised controlled trial. Lancet. 2002;359:1727-33.
0. Nygard K, Hagen S, Hansen HS, et al. Preoperative radiotherapy
prolongs survival in operable esophageal cancer: a randomised, mul-
ticenter study of pre-operative radiotherapy and chemotherapy: the
second Scandinavian trial in esophageal carcinoma. World J Surg.
1992;16:1104-10.
The Journal of Thoracic1. Le Prise E, Etienne PL, Meunier P, et al. A randomised study of
chemotherapy, radiation therapy, and surgery versus surgery for local-
ized squamous cell carcinoma of the esophagus. Cancer. 1994;73:
1179-84.
2. Walsh T, Noonan N, Hollywood D, Kelly A, Keeling N, Hennessy
TPJ. A comparison of multimodal therapy and surgery for esophageal
adenocarcinoma. N Engl J Med. 1996;335:462-7.
3. Bosset J-F, Gignoux M, Tiboulet J-P, et al. Chemoradiotherapy fol-
lowed by surgery compared with surgery alone in squamous cell
cancer of the esophagus. N Engl J Med. 1997;337:161-7.
4. Urba SG, Orriner MB, Turrisi A, Iannettoni M, Forastiere A, Straw-
derman M. Randomised trial of preoperative chemoradiotherapy ver-
sus surgery alone in patients with locoregional esophageal carcinoma.
J Clin Oncol. 2001;19:305-13.
5. Law S, Kwong D, Tung H, et al. Preoperative chemoradiation for
squamous cell esophageal cancer: a prospective randomised trial. Can
J Gastroenterol. 1998;12(Suppl B):56B [abstract].
6. Burmeister BH, Smithers BM, Gebski V, et al. Surgery alone versus
chemoradiotherapy followed by surgery for respectable cancer of the
oesophagus: a randomised controlled phase III trial. Lancet Oncol.
2005;6:659-68.
7. Siewert JR, Stein HJ. Classification of adenocarcinoma of the
oesophago-gastric junction. Br J Surg. 1998;85:1457-9.
8. Bone RC, Sibbald WJ, Spring CL. The ACCP-SCCM consensus
conference on sepsis and organ failure. Chest. 1992;101:1481-3.
9. Earlam R, Cunha-Melo JR. Oesophageal squamous cell carcinoma: I.
A critical review of surgery. Br J Surg. 1980;67:381-90.
0. Muller JM, Erasmi H, Stelzner M, Zieren U, Pichlmaier H. Surgical
therapy of oesophageal carcinoma. Br J Surg. 1990;77:845-7.
1. Jamieson GG, Mathew G, Ludeman R, Wayman J, Myers JC, Devitt
PG. Postoperative mortality following esophagectomy and problems in
reporting its rate. Br J Surg. 2004;91:943-97.
2. Bailey SH, Bull DA, Harpole DH, et al. Outcomes after esopha-
gectomy: a ten-year prospective cohort. Ann Thorac Surg. 2003;75:
217-22.
3. McCulloch P, Ward J, Tekkis P. Mortality and morbidity in gastro-
oesophageal cancer surgery: initial results of ASCOT multicentre
prospective study. BMJ. 2003;327:1192-7.
4. Van Lanschot JJ, Hulscher JB, Bueskens CJ, et al. Hospital volume
and hospital mortality for esophagectomy. Cancer. 2001;91:1574-8.
5. Begg CB, Cramer LD, Hoskins WJ, Brennan MF. Impact of hospital
volume on operative mortality for major cancer surgery. JAMA. 1998;
280:1747-51.
6. Fiorica F, DiBona D, Schepis F, et al. Preoperative chemoradiotherapy
for oesophageal cancer: a systematic review and meta-analysis. Gut.
2004;53:925-30.
7. Lee HK, Vaporciyan AA, Cox JD, et al. Postoperative pulmonary
complications after preoperative chemoradiation therapy for esopha-
geal carcinoma: correlation with dose-volume histogram parameters.
Int J Oncol Biol Phys. 2003;57:1317-22.
8. Heidecke CD, Weighardt H, Feith M, et al. Neoadjuvant treatment of
esophageal cancer: immunosuppression following combined radioche-
motherapy. Surgery. 2002;132:495-501.
9. Horwitz RI, Viscoli CM, Clemens JD, Sadock RT. Developing im-
proved observational methods for evaluating therapeutic effectiveness.
Am J Med. 1990;89:630-8.
0. Coleman CN, Stone HB, Moulder JE, Pellmar TC. Modulation of
radiation injury. Science. 2004;304:693-4.
and Cardiovascular Surgery ● Volume 132, Number 3 555
